



www.MedChemExpress.com











Inhibitors, Screening Libraries, Proteins

Thrombopoietin Receptor

Thrombopoietin (TPO) is the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the *c-mpl* gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

TPO binds to the thrombopoietin receptor (TPOr, also termed *c-mpl*) on platelets, megakaryocytes, and pluripotent stem cells leading to inhibition of apoptosis of stem cells and megakaryocytes; increased megakaryocyte number, size, and ploidy; increased rate of megakaryocyte maturation and platelet count; and decreased platelet threshold for activation by ADP and collagen.


Thrombopoietin Receptor Agonists

| | |
|---|--|
| <p>(E/Z)-Eltrombopag 13C4 (E/Z)-SB-497115 13C4) Cat. No.: HY-15306S</p> <p>(E/Z)-Eltrombopag 13C4 ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.</p> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 1 mg</p>  | <p>Avatrombopag (AKR-501; E5501; YM477) Cat. No.: HY-13463</p> <p>Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ($EC_{50}=3.3$ nM). Avatrombopag mimics the biological activities of TPO.</p> <p>Purity: >98% Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>  |
| <p>Avatrombopag hydrochloride (AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride) Cat. No.: HY-13463B</p> <p>Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ($EC_{50}=3.3$ nM). Avatrombopag hydrochloride mimics the biological activities of TPO.</p> <p>Purity: 98.53% Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>  | <p>Avatrombopag maleate (AKR-501 maleate; E5501 maleate; YM477 maleate) Cat. No.: HY-13463A</p> <p>Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ($EC_{50}=3.3$ nM). Avatrombopag maleate mimics the biological activities of TPO.</p> <p>Purity: >98% Clinical Data: Launched Size: 1 mg, 5 mg</p>  |
| <p>Avatrombopag-d8 hydrochloride (AKR-501-d8 hydrochloride; E5501-d8 hydrochloride; YM477-d8 hydrochloride) Cat. No.: HY-13463BS</p> <p>Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ($EC_{50}=3.3$ nM). Avatrombopag hydrochloride mimics the biological activities of TPO.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>  | <p>Eltrombopag (SB-497115) Cat. No.: HY-15306</p> <p>Eltrombopag (SB-497115) is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.</p> <p>Purity: 99.82% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>  |
| <p>Eltrombopag Olamine (Eltrombopag diethanolamine salt; SB-497115GR) Cat. No.: HY-15306A</p> <p>Eltrombopag Olamine (Eltrombopag diethanolamine salt) is a thrombopoietin-receptor agonist used to treat low blood platelet counts with chronic immune thrombocytopenia.</p> <p>Purity: 99.96% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>  | <p>Eltrombopag-d9 (SB-497115-d9) Cat. No.: HY-15306S1</p> <p>Eltrombopag-d9 (SB-497115-d9) is the deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>  |
| <p>Hetrombopag Cat. No.: HY-122620</p> <p>Hetrombopag is a potent thrombopoietin receptor agonist. Hetrombopag is efficacious and well tolerated with a manageable safety profile. Hetrombopag has the potential for the research of immune thrombocytopenia.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>  | <p>Lusutrombopag (S-888711) Cat. No.: HY-19883</p> <p>Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.</p> <p>Purity: 98.32% Clinical Data: Launched Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>  |

Lusutrombopag-d13 (S-888711-d13)

Cat. No.: HY-19883S

Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rafutrombopag

Cat. No.: HY-145589

Rafutrombopag is a **thrombopoietin (TPO)** agonist extracted from patent CN113929668 A.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TPO agonist 1

Cat. No.: HY-100380

TPO agonist 1 is a **thrombopoietin (TPO)** agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg